

Overview of Genzyme Corporation

Genzyme is one of the world's leading biotechnology companies. Its more than 11,000 employees work in countries throughout the world and are united by a common goal: to make a major positive impact on the lives of people with debilitating diseases.

Since its founding in 1981, Genzyme has grown from a small start-up to a diversified enterprise with 2008 revenues of \$4.6 billion. Over the past two decades Genzyme has introduced a number of breakthrough treatments in several areas of medicine, which have provided hope to patients who previously had no viable treatment options. Genzyme products are helping patients in 100 countries.

Today, Genzyme continues to be driven by its commitment to patients. The company is working to develop new medicines, improve its existing therapies, secure approvals for its products around the world, and ensure that patients have access to these treatments. Genzyme, which has its headquarters in Cambridge, Massachusetts, was chosen in 2007 to receive the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation.

Genzyme focuses on the following broad areas of medicine:

Genetic Diseases

Genzyme is a leader in the treatment of lysosomal storage disorders. These inherited diseases, which typically affect fewer than 10,000 people worldwide, are caused by enzyme deficiencies. Genzyme markets four enzyme replacement products to treat these diseases, which can be life-threatening.

- *Cerezyme*[®] (imiglucerase for injection) – for Gaucher disease type I.
- *Fabrazyme*[®] (agalsidase beta) – for Fabry disease.
- *Aldurazyme*[®] (laronidase) – for Mucopolysaccharidosis I.
- *Myozyme*[®] (αglucosidase alfa) – for Pompe disease.

Cardiometabolic & Renal

Genzyme currently markets five products in this area, including:

- *Renagel*[®] (sevelamer hydrochloride) is Genzyme's calcium-free, metal-free phosphate binder that reduces phosphorous levels in chronic kidney disease patients who are on dialysis.
- *Renvela*[®] (sevelamer carbonate) is a next-generation version of Renagel, currently approved in the U.S. for use in dialysis patients. Genzyme is

pursuing worldwide approvals and seeking to expand Renvela's indication to include patients with earlier stages of chronic kidney disease.

- *Hectorol*[®] (doxercalciferol) is a vitamin D₂ treatment for secondary hyperparathyroidism in chronic kidney disease patients.
- *Thyrogen*[®] (thyrotropin alfa for injection), is used in thyroid cancer follow-up, allowing patients to be screened without having to suspend thyroid hormone therapy. It is also approved in the U.S. and Europe for use in remnant ablation, a procedure patients commonly undergo when being treated for thyroid cancer.
- Cholestagel[®] (colesevelam hydrochloride) is marketed in Europe as an add-on therapy for hypercholesterolemic patients who cannot control their LDL cholesterol levels with a statin alone.

Oncology

- *Campath*[®] / *Mabcampath*[®] (alemtuzumab), is approved in the U.S. and Europe as a first-line treatment for B-cell chronic lymphocytic leukemia (B-CLL).
- *Clolar*[®] / *Evoltra*[®] (clofarabine), is approved in the U.S. and Europe for the treatment of children with refractory or relapsed acute lymphoblastic leukemia.
- Mozobil[™] (plerixafor), is approved in the U.S. for use in stem cell transplantation procedures in patients with non-Hodgkin's lymphoma and multiple myeloma.

Orthopaedics / Biosurgical Specialties

- *Synvisc*[®], *Synvisc-One*[™] (hylan G-F 20) Synvisc is one of the world's top therapies to treat the pain of osteoarthritis of the knee; Synvisc-One offers a new, single-injection treatment option.
- *Cartice*[®] (autologous cultured chondrocytes) is a cell-based therapy to help repair damaged knee cartilage currently marketed in the United States.
- *MACI*[®] (Matrix-induced Autologous Chondrocyte Implantation) is a cell-based therapy to help repair damaged knee cartilage currently marketed in Europe and Australia.
- *Seprafilm*[®] is designed to prevent painful and potentially debilitating adhesions following surgical procedures.

- *Epicel*[®] (cultured epidermal autografts) is a cell-based therapy for treating patients with severe, life-threatening burns.

Transplant

Thymoglobulin[®] (anti-thymocyte globulin, rabbit) treats acute rejection in kidney transplant patients by suppressing the body's natural immune response.

Genetics / Diagnostics

Genzyme is one of the largest providers of diagnostic testing services in the world, with expertise in reproductive and oncology testing. Genzyme is also a major supplier of point-of-care diagnostic products, with a focus on infectious diseases, diabetes, cardiovascular disease and kidney disease.

The company is playing an important role in the movement toward personalized medicine by developing tests that can help physicians identify how patients are likely to respond to targeted therapies.

Research and Development

Genzyme's research and development efforts are focused on the areas of medicine where it markets commercial products. The company also conducts research in cardiovascular disease, neurodegenerative diseases, and other areas of unmet medical need. In 2008, Genzyme invested approximately \$750 million in this work, or about 16 percent of its revenues.

Genzyme continues to build its pipeline through both internal research and licensing and acquisitions, focusing on product candidates with the potential to change the standard of care for serious diseases. The company's broad pipeline features seven major late-stage programs, including: alemtuzumab for multiple sclerosis; Clolar for adult acute myeloid leukemia; and mipomersen for familial hypercholesterolemia and other high risk, high cholesterol patients.

Corporate Responsibility

Corporate responsibility is a priority at Genzyme. The company's commitment to patients extends beyond the development of new treatments and the services needed to deliver them. Genzyme has a strong presence in developing countries, where it provides free medicine to patients and helps to build sustainable health care systems. The company in 2006 launched an initiative to support the development of treatments for neglected diseases that affect hundred of millions of people in the developing world. Genzyme's headquarters is one of the most environmentally responsible office buildings in the world, and the company is a leader in waste-reduction and recycling efforts.

In addition, Genzyme supports science education and health initiatives in the communities in which it operates. For these and other efforts, Genzyme has been consistently included in the Dow Jones Sustainability World Index, which consists of companies that excel in economic, environmental and social performance. For the past three years, Genzyme was named one of the "Global 100 Most Sustainable

Corporations in the World" by Innovest Strategic Value Advisors. BusinessWeek has ranked Genzyme as one of the top corporate givers, and the company has also been recognized by the U.S. Environmental Protection Agency, the American Association for the Advancement of Science, and many other organizations.

#